Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. - Wikidata - wikimedia - TriplyDB

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

http://www.wikidata.org/entity/Q34187441

about

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Diuretics for heart failure Aldosterone antagonists for preventing the progression of chronic kidney disease Diuretics for heart failure Aldosterone antagonists for preventing the progression of chronic kidney disease Aldosterone antagonists for preventing the progression of chronic kidney disease Diuretics for heart failure Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Male gynecomastia Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis Impact of Aldosterone Antagonists on Sudden Cardiac Death Prevention in Heart Failure and Post-Myocardial Infarction Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Recent advances in treatment of heart failure Review of the top 5 cardiology studies of 2013-14 Renocardiac syndromes: physiopathology and treatment stratagems Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone Heart failure in patients with chronic kidney disease: a systematic integrative review The autocrine/paracrine loop after myocardial stretch: mineralocorticoid receptor activation Erectile dysfunction in heart failure patients: a critical reappraisal Adipose tissue and adrenal glands: novel pathophysiological mechanisms and clinical applications The ubiquitous mineralocorticoid receptor: clinical implications Mineralocorticoid receptor blockade in chronic kidney disease Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems Mechanisms of altered Ca²⁺ handling in heart failure Aldosterone synthase inhibition in humans New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII)In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system Is there a new dawn for selective mineralocorticoid receptor antagonism?Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure Getting to the heart of intracellular glucocorticoid regeneration: 11β-HSD1 in the myocardium Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study

P2860

Q22242896-7D1B0162-1C13-4788-8389-96CA98AE4178 Q24185944-EBC30A97-546E-4957-93BB-2731B4C1E56A Q24194979-161EF9A7-EA1E-4B27-A95D-312A2F51FE2E Q24203661-81F63C22-0238-4B36-854C-C60C8335F6EB Q24239909-DDE5291D-D001-421C-BF22-9648FB62FC91 Q24243615-2F1617A5-D845-46BB-BFDD-390BACC9BF27 Q24244710-25543BAA-77D1-4350-8E5D-BF39083C1EB1 Q24531965-3D1641B6-A45A-4215-ADB8-673FA02B1F5A Q24604026-85AE7578-1BF7-4804-9F18-A26FA6E91139 Q24658187-03FAA0A1-BF17-45D2-8B31-D5C246F6BB2C Q26747017-12A6101C-D96F-425F-B1F8-403CDECFF2F4 Q26751460-C39F5CFB-4A11-46DE-B1D0-0ABDFD75A257 Q26764927-CC045FD4-FEF5-4960-B0E7-7F50172E2004 Q26766223-8DF7819C-1A6A-448B-85B2-522445B01A54 Q26776254-12024E07-C078-4E96-8847-30CB5C572BF7 Q26781936-148E5C70-EE34-46CE-9AB7-25FB3A0CEBB6 Q26783958-5761BF6D-12F6-4ECC-AC40-97D22BD759AB Q26785911-0CBF3348-D55A-4338-8A6D-4D375A8F922E Q26824149-F9C0D708-773C-4110-88C5-B1422522CB2A Q26826836-E4EE4F52-CC6B-4E97-8923-23C6A20CB872 Q26853624-8E01A416-C911-483B-8949-3BC11377EE99 Q26860227-A0A8FBA4-F5E1-423C-98C5-07C65372380E Q26861721-3151267E-CC85-4FEE-B05B-C54B0A61448E Q26864370-EF5EE6C3-73F2-4A91-A910-EECE2DA19A78 Q26999872-D7894A6E-E914-470B-895D-4FE7F05994F5 Q27000436-EABB4C1B-6ABB-46E6-807F-55A6D9E4E69F Q27003819-AD8B763B-C2A9-4AD3-B3F5-96765B0B230C Q27010641-5DAA50DD-1121-43F6-B3C7-093A8C5E1CB1 Q27012758-5AE067A1-0837-43D0-8406-F53325F88CE3 Q27016157-F8F404AA-FCC2-4D5B-B6FB-F9655E349812 Q27016402-8D55D387-94F6-4974-9DF6-F60B3EBFC1BD Q27026337-EB372A7B-FC16-4EDC-8C3F-C3B605191375 Q27027792-5CF9C48F-4C11-4635-8A1F-051F306FCAAA Q28066549-871AC641-1AD1-4BCD-A51E-2EEE6751A45F Q28067162-F1F5E943-C8B5-4105-9A35-EBBD5D3D5687 Q28077454-701407A4-A140-4C25-B6FC-310348140DD5 Q28087002-611F303B-92A0-487D-AF9C-E8D88A373DF0 Q28088583-5B76A2D3-C059-4120-B765-AE5890987E26 Q28182631-E80878E6-C4FC-4E49-9E3E-D13220BAD509 Q28239094-246CCD0E-C51C-4B58-B900-06851B965DB8

P2860

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

http://www.wikidata.org/entity/Q34187441

description

2003 nî lūn-bûn

@nan

2003 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի մարտին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Eplerenone, a selective aldost ...... n after myocardial infarction.

@ast

Eplerenone, a selective aldost ...... n after myocardial infarction.

@en

Eplerenone, a selective aldost ...... n after myocardial infarction.

@nl

type

label

Eplerenone, a selective aldost ...... n after myocardial infarction.

@ast

Eplerenone, a selective aldost ...... n after myocardial infarction.

@en

Eplerenone, a selective aldost ...... n after myocardial infarction.

@nl

prefLabel

Eplerenone, a selective aldost ...... n after myocardial infarction.

@ast

Eplerenone, a selective aldost ...... n after myocardial infarction.

@en

Eplerenone, a selective aldost ...... n after myocardial infarction.

@nl

P1433

Q34187441-47BF3E0D-2933-4A6D-9CF1-12CF9A57AE16

P1476

Q34187441-E1A3A5C0-ACE2-469B-B409-6832B7651903

P2093

Q34187441-1CF90878-10C8-4BFB-B4EF-4F565430AC67

Q34187441-3C8CCBF2-13C2-473C-B393-FF35E06794E4

Q34187441-50897870-B879-4DAA-8F84-3E445E34A440

Q34187441-508BAE85-3B31-4EC2-94A5-C0866ACA8F01

Q34187441-51766AD4-8E71-4BE3-BCD5-1F02CC8D58B5

Q34187441-53565B79-81D1-4AD7-B735-3DB9E95F964A

Q34187441-AD0CE7FA-AD3B-4706-8C37-C22ED4E7351E

Q34187441-E40636DD-D01F-414B-8636-69D49C4E8695

Q34187441-F5F8B0B3-F69D-474A-87B4-94759588E568

P304

Q34187441-8CC35AFB-FAC8-43A0-8692-4FCD5D95A93F

P31

Q34187441-B77EE7D1-B41B-405B-B183-CF8391029A02

P356

Q34187441-B61FA2C2-09AF-4D06-9380-A86CEDDDCA84

P407

Q34187441-662DB3D7-BB15-4CEA-B43A-0BCE3E16775E

P433

Q34187441-A71C6D27-FC3D-4A57-9ED5-1D7B81C8BAE3

P478

Q34187441-6FED48F1-65C0-46C3-BE70-421E4423499A

P50

Q34187441-612C7F07-0EB1-475B-A536-8D05277ABD04

Q34187441-D7869A6E-4DA5-4B49-AE09-F7BF11840F8C

P577

Q34187441-BBA8651D-1B68-4EE7-80BE-415E0E5BDF90

P5875

Q34187441-9115A14B-AD8A-4D5B-854A-754908AAC532

P698

Q34187441-09B2A306-4172-4BCA-BC67-53BAD811E8EE

P921

Q34187441-DFF0FFCE-FFA5-4A10-86F2-2FB50982C77C

Q34187441-E9126C10-0F06-4104-ABE1-A99CBBE33E65

P356

P1433

The New England Journal of Medicine

P1476

Eplerenone, a selective aldost ...... n after myocardial infarction.

@en

P2093

Barbara Roniker

http://www.w3.org/2001/XMLSchema#string

Eplerenone Post-Acute Myocardi ...... d Survival Study Investigators

http://www.w3.org/2001/XMLSchema#string

Felipe Martinez

http://www.w3.org/2001/XMLSchema#string

James Neaton

http://www.w3.org/2001/XMLSchema#string

Jay Kleiman

http://www.w3.org/2001/XMLSchema#string

Marjorie Gatlin

http://www.w3.org/2001/XMLSchema#string

Richard Bittman

http://www.w3.org/2001/XMLSchema#string

Steve Hurley

http://www.w3.org/2001/XMLSchema#string

Willem Remme

http://www.w3.org/2001/XMLSchema#string

P304

1309-1321

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA030207

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

348

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10827619

http://www.w3.org/2001/XMLSchema#string

P698

12668699

http://www.w3.org/2001/XMLSchema#string

P921